ポイントオブケア診断の市場規模、シェア、動向分析レポート：製品別、最終用途別、地域別、セグメント予測、2024年～2030年

ポイントオブケア（POT）診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のポイントオブケア診断市場規模は、2024年から2030年にかけて6.1%のCAGRを記録し、2030年には685億米ドルに達する見込みです。

テレヘルス対応のPOCTのような先進技術のイントロダクションが市場成長を促進すると予想されています。さらに、老年人口の増加と利用しやすい在宅ケアのニーズが市場を牽引すると予測されています。

アフリカやラテンアメリカなどの新興国におけるPOCTの採用は、世界のPOCT市場の成長決定要因になると予想されます。当局はヘルスケアシステムを分散化し、投資を増やしています。例えば、ケニアのアフリカ規制は、新しい機器の調達による施設の近代化に向けた政府の取り組みとして、マネージド機器サービスプロジェクトに346.7米ドルを割り当てた。保健省はGEヘルスとフィリップスを選び、47カ国に機器を提供しました。同様に、ラテンアメリカでは体外診断用医薬品の検査が分散化され、特に感染症分野では、この地域の手頃な価格のPOCTに対する既存の需要を満たすために、民間企業が戦略的イニシアチブを取ることを奨励しています。

現在開発されているPOC機器や検査は、がん、妊娠、感染症などさまざまな医療診断用途で採用されています。患者や医師は、POC検査を用いて病態をスクリーニングし、診断を確認し、患者の健康状態に基づいて適切な治療アプローチを設計します。しかし、医師、患者、介護者など、消費者によってその熱意は大きく異なります。このようなPOC診断製品のダイナミックな消費パターンは、経済的拡張性、経済的利益、普遍的ヘルスケア構造の欠如にも起因しています。

COVID-19に照らし合わせると、世界中でロックダウンが実施されたため、患者が病院を訪れずに済むよう支援するバーチャル訪問や迅速診断検査が必要となった。ロックダウン後、eヘルスケア戦略は、自動患者予約システム、検査結果送信システム、医療従事者のコミュニケーションシステム、企業や政府のための医療製品調達システムなど、優先順位と投資の新たな分野となっています。パンデミック後も、特に持病のある患者に対しては、在宅医療が優先されると予想されます。例えば、ニューロメトリックス社は、末梢神経障害のPOCTであるDPNCheckの事業開発のためのチームを任命しました。このチームは、ヘルスケア市場での足跡を拡大し、メディケア・アドバンテージ人口に焦点を当てる責任を負っています。

ポイントオブケア（POT）診断市場レポートハイライト：

• 感染症が市場をリードし、2023年の世界売上高シェアの27.8%を占めました。同分野の成長は、迅速検査に対する需要の高まりに起因しており、これが業界プレイヤーを分散型地域へのポイント・オブ・ケアソリューションの提供や革新的ソリューションの投入に向かわせた。
• 在宅部門は、在宅患者に提供されるポイントオブケア診断の快適さと費用対効果の高さから、予測期間中に最も高い成長率を示すと予測されています。POCT装置は使いやすく、患者サンプル中の簡便な標的分析物の検査に近代的なラボ・インフラを必要としないです。
• 北米が市場を独占し、2023年には42.9%のシェアを占めました。これは、新しいテクノロジーに対する需要の増加、主要プレイヤーの大規模なプール、高度なヘルスケアインフラによる。
• アジア太平洋地域は、がん、糖尿病、心血管疾患、感染症の有病率の上昇により、市場の大幅な成長が見込まれています。可処分所得が限られている人口の増加は、この地域の主要プレーヤーにとって潜在的なターゲット市場です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ポイントオブケア診断市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
  • 市場課題分析
  • 市場機会分析
• ポイントオブケア診断市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
• 製品別の価格分析
  • グルコース検査
  • Hb1Ac検査
  • 凝固検査
  • 不妊/妊娠
  • 感染症
  • HIV POC
  • クロストリジウム・ディフィシルPOC
  • HBV POC
  • 肺炎または連鎖球菌関連感染症
  • 呼吸器合胞体ウイルス（RSV）POC
  • HPV POC
  • インフルエンザ/インフルエンザ POC
  • HCV POC
  • MRSA POC
  • 結核と薬剤耐性結核のPOC
  • HSV POC
  • COVID-19
  • その他の感染症
  • 心臓マーカー
  • 甲状腺刺激ホルモン
  • 血液学
  • プライマリケアシステム
  • 分散型臨床化学
  • 糞便
  • 脂質検査
  • がんマーカー
  • 血液ガス/電解質
  • 外来化学
  • 乱用薬物（DOA）検査
  • 自己免疫疾患
  • 尿検査・腎臓学

第4章 ポイントオブケア診断市場：製品推定・動向分析

• 製品市場シェア、2023年と2030年
• セグメントダッシュボード
• 製品別の世界のポイントオブケア診断市場の見通し
• 市場規模、予測および動向分析、2018年から2030年まで

第5章 ポイントオブケア診断市場：最終用途の推定・動向分析

• 最終用途市場シェア、2023年および2030年
• セグメントダッシュボード
• 最終用途別の世界のポイントオブケア診断市場の見通し
• 市場規模、予測および動向分析、2018年から2030年まで

第6章 ポイントオブケア診断市場：地域推定・動向分析

• 地域市場シェア分析、2023年および2030年
• 地域市場ダッシュボード
• 世界の地域市場のスナップショット
• 市場規模と予測トレンド分析、2018年から2030年：
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • ロシア
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 会社/競合の分類
• ベンダー情勢
  • List of key distributors and channel partners
  • Key customers
  • Key company market share analysis, 2023
  • Company Profiles
  • Company Market Positioning Analysis, 2023
  • Key Parameters
  • Market Differentiators
  • Private Companies
  • Regional Mapping：Public and Private Companies

第8章 結論

List of Tables

• Table 1 List of abbreviation
• Table 2 North America point of care diagnostics market, by region, 2018 - 2030 (USD Billion)
• Table 3 North America point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 4 North America point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 5 U.S. point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 6 U.S. point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 7 Canada point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 8 Canada point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 9 Europe point of care diagnostics market, by region, 2018 - 2030 (USD Billion)
• Table 10 Europe point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 11 Europe point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 12 Germany point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 13 Germany point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 14 UK point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 15 UK point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 16 France point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 17 France point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 18 Italy point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 19 Italy point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 20 Spain point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 21 Spain point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 22 Russia point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 23 Russia point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 24 Denmark point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 25 Denmark point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 26 Sweden point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 27 Sweden point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 28 Norway point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 29 Norway point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 30 Asia Pacific point of care diagnostics market, by region, 2018 - 2030 (USD Billion)
• Table 31 Asia Pacific point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 32 Asia Pacific point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 33 China point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 34 China point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 35 Japan point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 36 Japan point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 37 India point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 38 India point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 39 South Korea point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 40 South Korea point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 41 Australia point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 42 Australia point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 43 Thailand point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 44 Thailand point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 45 Latin America point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 46 Latin America point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 47 Brazil point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 48 Brazil point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 49 Mexico point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 50 Mexico point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 51 Argentina point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 52 Argentina point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 53 MEA point of care diagnostics market, by region, 2018 - 2030 (USD Billion)
• Table 54 MEA point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 55 MEA point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 56 South Africa point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 57 South Africa point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 58 Saudi Arabia point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 59 Saudi Arabia point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 60 UAE point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 61 UAE point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 62 Kuwait point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 63 Kuwait point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Point of care diagnostics market: market outlook
• Fig. 14 Point of care diagnostics competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 Point of care diagnostics market driver impact
• Fig. 20 Point of care diagnostics market restraint impact
• Fig. 21 Point of care diagnostics market strategic initiatives analysis
• Fig. 22 Point of care diagnostics market: Product movement analysis
• Fig. 23 Point of care diagnostics market: Product outlook and key takeaways
• Fig. 24 Glucose testing market estimates and forecast, 2018 - 2030
• Fig. 25 Hb1Ac testing market estimates and forecast, 2018 - 2030
• Fig. 26 Coagulation testing market estimates and forecast, 2018 - 2030
• Fig. 27 Fertility/pregnancy market estimates and forecast, 2018 - 2030
• Fig. 28 Infectious disease market estimates and forecast, 2018 - 2030
• Fig. 29 HIV POC market estimates and forecast, 2018 - 2030
• Fig. 30 Pneumonia or streptococcus associated infections market estimates and forecasts, 2018 - 2030
• Fig. 31 Respiratory syncytial virus (RSV) POC market estimates and forecasts, 2018 - 2030
• Fig. 32 HPV POC market estimates and forecasts, 2018 - 2030
• Fig. 33 Influenza/ flu POC market estimates and forecasts, 2018 - 2030
• Fig. 34 HCV POC market estimates and forecasts, 2018 - 2030
• Fig. 35 MRSA POC market estimates and forecasts, 2018 - 2030
• Fig. 36 TB and drug resistant TB POC market estimates and forecasts, 2018 - 2030
• Fig. 37 HSV POC market estimates and forecasts, 2018 - 2030
• Fig. 38 COVID-19 market estimates and forecasts, 2018 - 2030
• Fig. 39 Other infectious diseases estimates and forecasts, 2018 - 2030
• Fig. 40 Cardiac markers market estimates and forecasts, 2018 - 2030
• Fig. 41 Thyroid stimulating hormone market estimates and forecasts, 2018 - 2030
• Fig. 42 Hematology market estimates and forecasts, 2018 - 2030
• Fig. 43 Primary care systems estimates and forecasts, 2018 - 2030
• Fig. 44 Decentralized clinical chemistry market estimates and forecasts, 2018 - 2030
• Fig. 45 Feces market estimates and forecasts, 2018 - 2030
• Fig. 46 Lipid testing market estimates and forecasts, 2018 - 2030
• Fig. 47 Cancer marker estimates and forecasts, 2018 - 2030
• Fig. 48 Blood gas/ electrolytes market estimates and forecasts, 2018 - 2030
• Fig. 49 Ambulatory chemistry market estimates and forecasts, 2018 - 2030
• Fig. 50 Drug of abuse (DoA) testing market estimates and forecasts, 2018 - 2030
• Fig. 51 Autoimmune diseases market estimates and forecasts, 2018 - 2030
• Fig. 52 Urinalysis/nephrology market estimates and forecasts, 2018 - 2030
• Fig. 53 Point of care diagnostics market: end use movement analysis
• Fig. 54 Point of care diagnostics market: end use outlook and key takeaways
• Fig. 55 Clinics market estimates and forecasts, 2018 - 2030
• Fig. 56 Pharmacy & retail clinics market estimates and forecasts, 2018 - 2030
• Fig. 57 Physician office market estimates and forecasts, 2018 - 2030
• Fig. 58 Urgent care clinics market estimates and forecasts, 2018 - 2030
• Fig. 59 Non-practice clinics market estimates and forecasts, 2018 - 2030
• Fig. 60 Hospitals market estimates and forecasts, 2018 - 2030
• Fig. 61 Home market estimates and forecasts, 2018 - 2030
• Fig. 62 Assisted living healthcare facilities market estimates and forecasts, 2018 - 2030
• Fig. 63 Laboratory market estimates and forecasts, 2018 - 2030
• Fig. 64 Global point of care diagnostics market: Regional movement analysis
• Fig. 65 Global point of care diagnostics market: Regional outlook and key takeaways
• Fig. 66 Global point of care diagnostics market share and leading players
• Fig. 67 North America market share and leading players
• Fig. 68 Europe market share and leading players
• Fig. 69 Asia Pacific market share and leading players
• Fig. 70 Latin America market share and leading players
• Fig. 71 Middle East & Africa market share and leading players
• Fig. 72 North America: SWOT
• Fig. 73 Europe SWOT
• Fig. 74 Asia Pacific SWOT
• Fig. 75 Latin America SWOT
• Fig. 76 MEA SWOT
• Fig. 77 North America, by country
• Fig. 78 North America
• Fig. 79 North America market estimates and forecasts, 2018 - 2030
• Fig. 80 U.S. key country dynamics
• Fig. 81 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 82 Canada country dynamics
• Fig. 83 Canada market estimates and forecasts, 2018 - 2030
• Fig. 84 Europe
• Fig. 85 Europe market estimates and forecasts, 2018 - 2030
• Fig. 86 UK country dynamics
• Fig. 87 UK market estimates and forecasts, 2018 - 2030
• Fig. 88 Germany country dynamics
• Fig. 89 Germany market estimates and forecasts, 2018 - 2030
• Fig. 90 France country dynamics
• Fig. 91 France market estimates and forecasts, 2018 - 2030
• Fig. 92 Italy country dynamics
• Fig. 93 Italy market estimates and forecasts, 2018 - 2030
• Fig. 94 Spain country dynamics
• Fig. 95 Spain market estimates and forecasts, 2018 - 2030
• Fig. 96 Russia country dynamics
• Fig. 97 Russia market estimates and forecasts, 2018 - 2030
• Fig. 98 Denmark country dynamics
• Fig. 99 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 100 Sweden country dynamics
• Fig. 101 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 102 Norway country dynamics
• Fig. 103 Norway market estimates and forecasts, 2018 - 2030
• Fig. 104 Asia Pacific
• Fig. 105 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 106 China country dynamics
• Fig. 107 China market estimates and forecasts, 2018 - 2030
• Fig. 108 Japan country dynamics
• Fig. 109 Japan market estimates and forecasts, 2018 - 2030
• Fig. 110 India country dynamics
• Fig. 111 India market estimates and forecasts, 2018 - 2030
• Fig. 112 Thailand country dynamics
• Fig. 113 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 114 South Korea country dynamics
• Fig. 115 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 116 Australia country dynamics
• Fig. 117 Australia market estimates and forecasts, 2018 - 2030
• Fig. 118 Latin America
• Fig. 119 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 120 Brazil country dynamics
• Fig. 121 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 122 Mexico country dynamics
• Fig. 123 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 124 Argentina country dynamics
• Fig. 125 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 126 Middle East and Africa
• Fig. 127 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 128 South Africa country dynamics
• Fig. 129 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 130 Saudi Arabia country dynamics
• Fig. 131 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 132 UAE country dynamics
• Fig. 133 UAE market estimates and forecasts, 2018 - 2030
• Fig. 134 Kuwait country dynamics
• Fig. 135 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 136 Market share of key market players- Point of care diagnostics market

Point Of Care Diagnostics Market Growth & Trends:

The global point of care diagnostics market size is expected to reach USD 68.5 billion by 2030, registering a CAGR of 6.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The introduction of advanced technologies such as Telehealth enabled POCT is expected to fuel market growth. Furthermore, the rise in the geriatric population and their need for accessible home-based care are anticipated to drive the market.

The adoption of POCT in emerging economies such as Africa and Latin America is anticipated to be a growth determinant of the global POCT market. The authorities are decentralizing the healthcare system and increasing their investments. For instance, the African regulations in Kenya allotted USD 346.7 to Managed Equipment Services project for the government's initiative toward modernizing facilities by procuring new equipment. The Ministry of Health selected GE Health and Philips to offer equipment across 47 countries. Similarly, Latin America decentralized IVD testing, which encourages private players to take strategic initiatives to meet the region's existing demand for affordable POCT, especially in the infectious diseases segment.

Currently developed POC devices and tests are employed across different medical diagnostic applications, including cancer, pregnancy, and infectious diseases. Patients and physicians employ POC tests to screen conditions, confirm diagnoses, and design suitable therapeutic approaches based on patient health. However, the enthusiasm displayed by different consumers, such as doctors, patients, and caregivers, varies widely. This dynamic consumption pattern of POC diagnostic products is also attributed to economic scalability, financial interests, and lack of a universal healthcare structure.

In the light of COVID-19, the lockdown imposed across the globe has necessitated virtual visits and rapid diagnostic tests that assist patients to avoid hospital visits. Post-lockdown, the eHealth strategy is the emerging area of priority and investment such as an automated patient appointment system, lab result transmission system, healthcare workers' communication system, and medical products procurement system for the companies and governments. It is anticipated to continue to prioritize home-based healthcare delivery even after the pandemic, especially for patients with pre-existing conditions. For instance, NeuroMetrix, Inc. appointed a team to develop the business of DPNCheck, a POCT for peripheral neuropathies. The team is responsible for expanding the footprint in the healthcare market and focusing on the Medicare Advantage population.

Point Of Care Diagnostics Market Report Highlights:

• The Infectious disease led the market and accounted for 27.8% of global revenue share in 2023. Growth of the segment is attributed to increasing demand for rapid tests, which has encouraged industry players to deliver point of care solutions to decentralized regions and launch innovative solutions.
• Home sector is projected to witness the highest growth rate over the forecast period owing to the comfort level and cost-effectiveness of point of care diagnostics provided to patients at home. POCT devices are easy to use and do not, mandatorily, require any modern lab infrastructure for testing simpler target analytes in a patient's sample
• North America dominated the market and accounted for a 42.9% share in 2023 owing to the increasing demand for new technologies, a large pool of key players, and advanced healthcare infrastructure
• The Asia Pacific is anticipated to witness significant growth in the market owing to the rising prevalence of cancer, diabetes, cardiovascular diseases, and infectious diseases. The increasing population with limited disposable income is the potential target market for the key players in the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. End Use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Point Of Care Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Introduction of CLIA waived tests
    • 3.2.1.2. Rise in funding from government and private institutions
    • 3.2.1.3. Growing geriatric population base
    • 3.2.1.4. Growing prevalence of target diseases
    • 3.2.1.5. Growing demand for home healthcare and the introduction of advance technology enabled products
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High procedure costs coupled with limited adoption of POC devices in certain emerging regions
    • 3.2.2.2. Presence of ambiguous regulatory as well as reimbursement frame work for primary care setting
  • 3.2.3. Market challenge analysis
    • 3.2.3.1. POC device pose challenges in maintaining the quality standards
  • 3.2.4. Market opportunity analysis
    • 3.2.4.1. Networking & remote integration of POC diagnostics products
      • 3.2.4.1.1. Smartphone orientation
      • 3.2.4.1.2. Embedded vision based solutions
      • 3.2.4.1.3. Digital technologies
• 3.3. Point Of Care Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Pricing Analysis, By Product
  • 3.4.1. Glucose Testing
  • 3.4.2. Hb1Ac Testing
  • 3.4.3. Coagulation Testing
  • 3.4.4. Fertility/Pregnancy
  • 3.4.5. Infectious Disease
  • 3.4.6. HIV POC
  • 3.4.7. Clostridium Difficile POC
  • 3.4.8. HBV POC
  • 3.4.9. Pneumonia or Streptococcus Associated Infections
  • 3.4.10. Respiratory Syncytial Virus (RSV) POC
  • 3.4.11. HPV POC
  • 3.4.12. Influenza/Flu POC
  • 3.4.13. HCV POC
  • 3.4.14. MRSA POC
  • 3.4.15. TB and Drug-resistant TB POC
  • 3.4.16. HSV POC
  • 3.4.17. COVID-19
  • 3.4.18. Other Infectious Diseases
  • 3.4.19. Cardiac Markers
  • 3.4.20. Thyroid Stimulating Hormone
  • 3.4.21. Hematology
  • 3.4.22. Primary Care Systems
  • 3.4.23. Decentralized Clinical Chemistry
  • 3.4.24. Feces
  • 3.4.25. Lipid Testing
  • 3.4.26. Cancer Marker
  • 3.4.27. Blood Gas/Electrolytes
  • 3.4.28. Ambulatory Chemistry
  • 3.4.29. Drug of Abuse (DOA) Testing
  • 3.4.30. Autoimmune Diseases
  • 3.4.31. Urinalysis/Nephrology

Chapter 4. Point Of Care Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Point Of Care Diagnostics Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Glucose Testing
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.2. Hb1Ac Testing
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.3. Coagulation Testing
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.4. Fertility/Pregnancy Testing
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.5. Infectious Disease
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5.2. HIV POC
      • 4.4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5.3. Clostridium Difficile POC
      • 4.4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5.4. HBV POC
      • 4.4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5.5. Pneumonia or Streptococcus Associated Infections
      • 4.4.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5.6. Respiratory Syncytial Virus (RSV) POC
      • 4.4.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5.7. HPV POC
      • 4.4.5.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5.8. Influenza/Flu POC
      • 4.4.5.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5.9. HCV POC
      • 4.4.5.9.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5.10. MRSA POC
      • 4.4.5.10.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5.11. TB and drug resistant TB POC
      • 4.4.5.11.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5.12. HSV POC
      • 4.4.5.12.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5.13. COVID-19
      • 4.4.5.13.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5.14. Other infectious diseases
      • 4.4.5.14.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.6. Cardiac Markers
    • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.7. Thyroid Stimulating Hormone
    • 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.8. Hematology
    • 4.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.9. Primary Care Systems
    • 4.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.10. Decentralized Clinical Chemistry
    • 4.4.10.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.11. Feces
    • 4.4.11.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.12. Lipid Testing
    • 4.4.12.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.13. Cancer Marker
    • 4.4.13.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.14. Blood Gas/Electrolytes
    • 4.4.14.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.15. Ambulatory Chemistry
    • 4.4.15.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.16. Drug of Abuse (DOA) Testing
    • 4.4.16.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.17. Autoimmune diseases
    • 4.4.17.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.18. Urinalysis/Nephrology
    • 4.4.18.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Point Of Care Diagnostics Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Point Of Care Diagnostics Market by End Use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Clinics
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD billion)
    • 5.4.1.2. Pharmacy & Retail Clinics
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.1.3. Physician Office
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.1.4. Urgent Care Clinics
      • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.1.5. Non-practice Clinics
      • 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.2. Hospitals
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.3. Home
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.4. Assisted Living Healthcare Facilitates
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.5. Laboratory
    • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Point Of Care Diagnostics Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2023 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Europe
  • 6.6.1. Germany
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.2. UK
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.6. Russia
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Russia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.7. Norway
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.8. Sweden
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.9. Denmark
    • 6.6.9.1. Key country dynamics
    • 6.6.9.2. Regulatory framework/ reimbursement structure
    • 6.6.9.3. Competitive scenario
    • 6.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.4. South Korea
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.5. Australia
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8.2. Mexico
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8.3. Argentina
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/ reimbursement structure
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
    • 7.3.1.1. Abbott
    • 7.3.1.2. Alere Inc.
    • 7.3.1.3. F. Hoffmann-La Roche Ltd.
    • 7.3.1.4. Siemens Healthcare GmbH
    • 7.3.1.5. Danaher Corporation
    • 7.3.1.6. Werfen
    • 7.3.1.7. BD
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. Company Profiles
    • 7.3.4.1. F. Hoffmann-La Roche Ltd.
      • 7.3.4.1.1. Company overview
      • 7.3.4.1.2. Financial performance
      • 7.3.4.1.3. Product benchmarking
      • 7.3.4.1.4. Strategic initiatives
    • 7.3.4.2. Qiagen
      • 7.3.4.2.1. Company overview
      • 7.3.4.2.2. Financial performance
      • 7.3.4.2.3. Product benchmarking
      • 7.3.4.2.4. Strategic initiatives
    • 7.3.4.3. Danaher Corporation
      • 7.3.4.3.1. Company overview
      • 7.3.4.3.2. Financial performance
      • 7.3.4.3.3. Product benchmarking
      • 7.3.4.3.4. Strategic initiatives
    • 7.3.4.4. Becton Dickinson (BD)
      • 7.3.4.4.1. Company overview
      • 7.3.4.4.2. Financial performance
      • 7.3.4.4.3. Product benchmarking
      • 7.3.4.4.4. Strategic initiatives
    • 7.3.4.5. bioMerieux
      • 7.3.4.5.1. Company overview
      • 7.3.4.5.2. Financial performance
      • 7.3.4.5.3. Product benchmarking
      • 7.3.4.5.4. Strategic initiatives
    • 7.3.4.6. Abbott
      • 7.3.4.6.1. Company overview
      • 7.3.4.6.2. Financial performance
      • 7.3.4.6.3. Product benchmarking
      • 7.3.4.6.4. Strategic initiatives
    • 7.3.4.7. Siemens Healthcare GmbH
      • 7.3.4.7.1. Company overview
      • 7.3.4.7.2. Financial performance
      • 7.3.4.7.3. Product benchmarking
      • 7.3.4.7.4. Strategic initiatives
    • 7.3.4.8. Werfen
      • 7.3.4.8.1. Company overview
      • 7.3.4.8.2. Financial performance
      • 7.3.4.8.3. Product benchmarking
      • 7.3.4.8.4. Strategic initiatives
    • 7.3.4.9. Nova Biomedical
      • 7.3.4.9.1. Company overview
      • 7.3.4.9.2. Financial performance
      • 7.3.4.9.3. Product benchmarking
      • 7.3.4.9.4. Strategic initiatives
    • 7.3.4.10. Trividia Health, Inc.
      • 7.3.4.10.1. Company overview
      • 7.3.4.10.2. Financial performance
      • 7.3.4.10.3. Product benchmarking
      • 7.3.4.10.4. Strategic initiatives
    • 7.3.4.11. QuidelOrtho Corporation
      • 7.3.4.11.1. Company overview
      • 7.3.4.11.2. Financial performance
      • 7.3.4.11.3. Product benchmarking
      • 7.3.4.11.4. Strategic initiatives
    • 7.3.4.12. Trinity Biotech
      • 7.3.4.12.1. Company overview
      • 7.3.4.12.2. Financial performance
      • 7.3.4.12.3. Product benchmarking
      • 7.3.4.12.4. Strategic initiatives
    • 7.3.4.13. Sekisui Diagnostics
      • 7.3.4.13.1. Company overview
      • 7.3.4.13.2. Financial performance
      • 7.3.4.13.3. Product benchmarking
      • 7.3.4.13.4. Strategic initiatives
    • 7.3.4.14. Orasure Technologies, Inc.
      • 7.3.4.14.1. Company overview
      • 7.3.4.14.2. Financial performance
      • 7.3.4.14.3. Product benchmarking
      • 7.3.4.14.4. Strategic initiatives
    • 7.3.4.15. Spectral Medical, Inc.
      • 7.3.4.15.1. Company overview
      • 7.3.4.15.2. Financial performance
      • 7.3.4.15.3. Product benchmarking
      • 7.3.4.15.4. Strategic initiatives
    • 7.3.4.16. EKF Diagnostics Holdings plc.
      • 7.3.4.16.1. Company overview
      • 7.3.4.16.2. Financial performance
      • 7.3.4.16.3. Product benchmarking
      • 7.3.4.16.4. Strategic initiatives
    • 7.3.4.17. Anbio Biotechnology Co., Ltd.
      • 7.3.4.17.1. Company overview
      • 7.3.4.17.2. Financial performance
      • 7.3.4.17.3. Product benchmarking
      • 7.3.4.17.4. Strategic initiatives
    • 7.3.4.18. AccuBioTech Co., Ltd.
      • 7.3.4.18.1. Company overview
      • 7.3.4.18.2. Financial performance
      • 7.3.4.18.3. Product benchmarking
      • 7.3.4.18.4. Strategic initiatives
    • 7.3.4.19. ALPHA LABORATORIES
      • 7.3.4.19.1. Company overview
      • 7.3.4.19.2. Financial performance
      • 7.3.4.19.3. Product benchmarking
      • 7.3.4.19.4. Strategic initiatives
  • 7.3.5. Company Market Positioning Analysis, 2023
    • 7.3.5.1. Glucose Monitoring
    • 7.3.5.2. Cardiac Markers
    • 7.3.5.3. Hematology
    • 7.3.5.4. Coagulation
    • 7.3.5.5. Fertility Testing
    • 7.3.5.6. Infectious Diseases
    • 7.3.5.7. Decentralized Clinical Chemistry
    • 7.3.5.8. Oncology Markers
    • 7.3.5.9. Blood Gas Testing
    • 7.3.5.10. Ambulatory Testing
    • 7.3.5.11. Drug of Abuse
    • 7.3.5.12. Urinalysis
  • 7.3.6. Key Parameters
    • 7.3.6.1. Company Size
    • 7.3.6.2. Geographic Presence
    • 7.3.6.3. Production Portfolio
    • 7.3.6.4. Collaborations
  • 7.3.7. Market Differentiators
    • 7.3.7.1. Application Trends
    • 7.3.7.2. Technology Trends
    • 7.3.7.3. Test Location Trends
    • 7.3.7.4. End-use Trends
    • 7.3.7.5. Regional Trends
  • 7.3.8. Private Companies
    • 7.3.8.1. New Entrants/Emerging Players
  • 7.3.9. Regional Mapping: Public and Private Companies

Chapter 8. Conclusion